Anteris Technologies Global Corp. — Capital/Financing Update 2018

Dec 13, 2018

14 December 2018

==> picture [451 x 24] intentionally omitted <==

ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000

Admedus Limited (ASX:AHZ)

ENTITLEMENT OFFER SHORTFALL NOTICE

Admedus Limited ( Admedus ) advises that the partially underwritten renounceable pro-rata entitlement offer announced to ASX on Wednesday, 28 November 2018 ( Entitlement Offer ) closed on Thursday, 13 December 2018 (the Closing Date ).

The Entitlement Offer gave eligible shareholders the opportunity to participate by offering the right to subscribe for 5 new Shares for every 7 existing shares held at an issue price of $0.08 per new Share. Each new Share included 1 free attaching new Option with an exercise price of $0.08 that expires 3 years from the date of issue.

Through the Entitlement Offer the Company will issue 237,052,479 New Shares and 237,052,479 New Options to raise $18,964,198 (before fees and costs).

The results of the Entitlement Offer are as follows:

The results of the Entitlement Offer are as	follows:
	$	New Shares	New Options
Total number of new securities offered	20,165,063	252,063,292	252,063,292
Number of new securities applied for	5,374,530	67,181,628	67,181,628
Shortfall securities to be placed with the	13,589,668	169,870,851	169,870,851
underwriters
Balance of shortfall securities	1,200,865	15,010,813	15,010,813

Admedus Limited

Registered Office: Level 9, 301 Coronation Drive, Milton, Queensland 4064

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299 E: info@admedus.com W: admedus.com

==> picture [72 x 72] intentionally omitted <==

Brisbane • Minneapolis • Geneva • Singapore

ABN 35 088 221 078

==> picture [451 x 24] intentionally omitted <==

169,870,851 New Shares and 169,870,851 attaching New Options will be placed with the underwriters in accordance with the Underwriting Agreements as disclosed in the Prospectus for the Entitlement Offer lodged with the ASX on Wednesday, 28 November 2018 (the Prospectus ). Admedus has notified each of the underwriters of their entitlement issue shortfall.

As noted in the Prospectus, the Directors of Admedus reserve the right to place the balance of shortfall securities within three months after the Closing Date to either existing or new shareholders at their discretion.

The new Shares and new Options issued under the Entitlement Offer are expected to be allotted on Monday, 17 December 2018, with holding statements to be despatched on Wednesday, 19 December 2018.

The anticipated date for commencement of normal trading of the new Shares on ASX is Tuesday, 18 December 2018.

ENDS

==> picture [24 x 25] intentionally omitted <==

==> picture [451 x 24] intentionally omitted <==

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus Twitter: @Admedus

For more information, please contact:

Share Registry

Computershare Investor Services Pty Ltd Telephone: 1300 557 010 (within Aust) +61 3 9415 4000 (outside Aust) Facsimile: +61 3 9473 2500

Investor Relations

Kyahn Williamson WE Buchan Admedus@we-buchan.com 03 9866 4722

==> picture [24 x 25] intentionally omitted <==